Frankfurt - Delayed Quote EUR

Viking Therapeutics, Inc. (1VT.F)

23.63
+0.03
+(0.15%)
As of 8:07:31 AM GMT+2. Market Open.
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
172,317
150,921
100,827
70,355
55,682
Operating Income
-172,317
-150,921
-100,827
-70,355
-55,682
Net Non Operating Interest Income Expense
43,969
40,846
14,932
1,530
685
Other Income Expense
--
112
--
-42
7
Pretax Income
-128,236
-109,963
-85,895
-68,867
-54,990
Net Income Common Stockholders
-128,236
-109,963
-85,895
-68,867
-54,990
Diluted NI Available to Com Stockholders
-128,236
-109,963
-85,895
-68,867
-54,990
Basic EPS
-1.16
--
-0.91
-0.90
-0.71
Diluted EPS
-1.16
--
-0.91
-0.90
-0.71
Basic Average Shares
111,190.07
--
94,347
76,834
77,198
Diluted Average Shares
111,190.07
--
94,347
76,834
77,198
Total Operating Income as Reported
-172,317
-150,921
-100,827
-70,355
-55,682
Total Expenses
172,317
150,921
100,827
70,355
55,682
Net Income from Continuing & Discontinued Operation
-128,236
-109,963
-85,895
-68,867
-54,990
Normalized Income
-128,348
-110,075
-85,895
-68,825
-54,997
Interest Income
44,059
40,940
15,020
1,589
703
Net Interest Income
43,969
40,846
14,932
1,530
685
EBIT
-172,317
-150,921
-100,827
-70,355
-55,682
EBITDA
-171,934
-150,575
-100,535
-70,064
-55,386
Reconciled Depreciation
383
346
292
291
296
Net Income from Continuing Operation Net Minority Interest
-128,236
-109,963
-85,895
-68,867
-54,990
Total Unusual Items Excluding Goodwill
112
112
--
-42
7
Total Unusual Items
112
112
--
-42
7
Normalized EBITDA
-172,046
-150,687
-100,535
-70,022
-55,393
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 5/11/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers